Letter: serum <scp>HB</scp>crAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection

Wang, M.‐L.; Chen, E.‐Q.; Tao, Chuanmin; Tang, Hong

doi:10.1111/apt.14673

Cited by 5 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to serum HBsAg and HBV DNA level, serum HBcrAg had a better correlation with intrahepatic cccDNA 17 . Evidence is accumulating that HBcrAg could predict the response to NAs therapy, off‐treatment viral relapse, HBeAg seroconversion and the risk of development to HCC 18 . Wang and colleagues revealed that the quantitative serum HBsAg and HBcrAg could predict the HBeAg seroconversion in HBeAg‐positive patients treated with NAs 19 …”

Section: Introductionmentioning

confidence: 99%

“…17 Evidence is accumulating that HBcrAg could predict the response to NAs therapy, off-treatment viral relapse, HBeAg seroconversion and the risk of development to HCC. 18 Wang and colleagues revealed that the quantitative serum HBsAg and HBcrAg could predict the HBeAg seroconversion in HBeAg-positive patients treated with NAs. 19 It has been reported that correlation between new markers (HBcrAg and HBV RNA) and HBeAg clearance or seroconversion is better than that of the traditional markers (HBsAg and HBV DNA).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues

Wang

Liao

Deng

et al. 2022

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Background: To evaluate the predictive value of serum HBV DNA, HBV RNA, HBcrAg, HBsAg, intrahepatic HBV DNA, and cccDNA for HBeAg clearance and seroconversion during long-term treatment of nucleos(t)ide analogues (NAs) in patients with chronic hepatitis B (CHB).Method: A single center, prospective cohort of CHB patients enrolled between June 2007 and July 2008 was used for this study. Serum HBV RNA levels were retrospectively measured at baseline, 6, 12, 24, 36, 48, 60, 72, and 84 months post-NAs treatment. Serum HBsAg and HBcrAg levels were quanti ed at baseline, month 6, 60, and 72. Histological sample from liver biopsy at baseline and month 60 were analyzed for intrahepatic HBV DNA and cccDNA.Results: Eighty-three HBeAg patients were enrolled with an median follow-up time of 108 months (range 18-138 months). Of them, 53 (63.86%) patients achieved HBeAg clearance, and 37 (44.58%) achieved HBeAg seroconversion. Only baseline HBV RNA was independently associated with HBeAg clearance (OR=0.50, 95%CI 0.309-0.809, P=0.005) and seroconversion (OR=0.689, 95% CI 0.513-0.925, P=0.013). The independent negative association with HBeAg clearance and seroconversion remained for HBV RNA levels at month 6 (OR=0.42, 95%CI 0.248-0.714, P=0.001; OR=0.44, 95%CI 0.260-0.744, P=0.002) and month 12 (OR=0.39, 95%CI 0.253-0.592, P<0.001; OR=0.58, 95%CI 0.427-0.798, P=0.001). The AUC of baseline HBV RNA for predicting the HBeAg clearance and seroconversion were 0.81 (95%CI: 0.70-0.89) and 0.68 (95%CI: 0.56-0.78), respectively, higher than that of HBV DNA, HBsAg and HBcrAg. Conclusion: Lower serum HBV RNA at baseline, month 6 and 12 post NAs treatment could predict HBeAg clearance and seroconversion during long-term NAs treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues

Wang

Liao

Deng

et al. 2022

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…In our previous studies, early on‐treatment serum HBcrAg level was found to be a good biomarker for predicting off‐treatment HBeAg seroconversion in patients receiving peginterferon therapy, and as compared to serum HBsAg level, serum HBcrAg has a better correlation with intrahepatic cccDNA . In addition, patients with low HBcrAg and HBsAg levels are also reported to have a low relapse risk after cessation of antiviral therapy …”

Section: Introductionmentioning

confidence: 99%

“…6,9 In addition, patients with low HBcrAg and HBsAg levels are also reported to have a low relapse risk after cessation of antiviral therapy. 10,11 Recently, serum HBV RNA is also attracting attention as a useful biomarker. 12,13 As early as 1996, serum HBV RNA was identified in HBV-infected patients but its nature and origin were unclear until recently when serum HBV RNA was confirmed to be pregenomic RNA (pgRNA).…”

Section: Introductionmentioning

confidence: 99%

Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA

Chen

Wang

Tao

et al. 2019

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

Summary The correlation between serum HBcrAg and HBV RNA is unclear, and correlations of intrahepatic cccDNA with HBcrAg, HBV RNA and HBsAg are rarely reported in the same cohort. This study aimed to assess the correlation of HBcrAg with HBV RNA and HBsAg, and investigate whether serum HBcrAg is superior to serum HBV RNA and HBsAg in reflecting intrahepatic HBV cccDNA in HBeAg‐positive and HBeAg‐negative CHB patients. In this study, 85 HBeAg‐positive and 25 HBeAg‐negative patients who have never received antiviral therapy were included. Among HBeAg‐positive patients, HBcrAg was correlated positively with HBsAg (r = 0.564, P < 0.001) and HBV RNA (r = 0.445, P < 0.001), and HBV RNA was also correlated positively with HBsAg (r = 0.323, P = 0.003). Among HBeAg‐negative patients, no significant correlation was observed between HBcrAg, HBsAg and HBV RNA. By multivariable linear regression, HBcrAg (β = −0.563, P < 0.001), HBsAg (β = −0.328, P < 0.001) and HBV RNA (β = 0.180, P = 0.003) were all associated with cccDNA levels among HBeAg‐positive patients, but only serum HBcrAg was associated with cccDNA level (β = 0.774, P = 0.000) among HBeAg‐negative patients. HBcrAg was better correlated with cccDNA as compared to HBsAg and HBV RNA, irrespective of HBeAg status. Among HBeAg‐positive patients, though HBcrAg level was influenced by hepatic inflammatory activity and HBV DNA levels, the good correlations of HBcrAg with cccDNA persisted after stratification by inflammatory activity and HBV DNA levels. In conclusion, correlations of serum HBcrAg, HBV RNA and HBsAg levels differ significantly between HBeAg‐positive and HBeAg‐negative patients, but serum HbcrAg correlates with cccDNA levels better than HBV RNA and HBsAg, irrespective of HBeAg status.

show abstract

“…7 In past decade, many studies suggested that monitoring the baseline and early on-treatment levels of serum HBsAg and HBcrAg would also help to reflect intrahepatic cccDNA levels and predict viral relapse risk after cessation of nucleotide analogs (NAs). [9][10][11] Additionally, serum HBsAg levels could be used to evaluate the treatment of already available agents (such as pegylated interferon and NAs) whether should be optimized or adjusted. 12,13 Unfortunately, correlations between serum HBV pgRNA, HBsAg, and HBcrAg levels are rarely head-to-head compared, and it is still unclear whether these viral serum markers can be replaced by each other.…”

mentioning

confidence: 99%

Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients

Liao

Ye²,

Tao

et al. 2020

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Correlations between serum hepatitus B virus (HBV) pregenomic RNA (pgRNA), hepatitus B surface antigen (HBsAg), and hepatitus B core‐related antigen (HBcrAg) levels, and influencing factors of serum HBV pgRNA levels in Chinese chronic hepatitis B (CHB) patients are rarely reported. This was a retrospective cohort study consisting of 204 outpatients with CHB. Serum levels of HBV pgRNA, HBsAg, and HBcrAg were quantitative measured in frozen blood samples. The linear regression and multivariate logistic regression analysis were performed to determine associated factors of serum HBV pgRNA levels. In this cohort, the median serum HBV pgRNA level was 4.12 log10 copies/ml and 33.33% (68/204) of them had serum HBV pgRNA under low limit of detection (LLD) (<500 copies/ml); and the percentage of patients with serum HBV pgRNA under LLD in hepatitis B e antigen (HBeAg)‐positive patients was significantly lower than that in HBeAg‐negative patients (15.75% [23/46] vs. 77.59% [45/58], p < .001). Overall, serum HBV pgRNA strongly correlated with HBcrAg (r = 0.760, p < .001), and moderately correlated with HBV DNA (r = 0.663, p < .001) and HBsAg (r = 0.670, p < .001). As compared with HBsAg and HBV DNA, only HBcrAg showed stable correlation with serum HBV pgRNA both in HBeAg‐positive and HBeAg‐negative patients. Serum HBV pgRNA level differed between HBeAg‐positive and HBeAg‐negative patients; and it had better and more stable correlation with serum HBcrAg than serum HBV DNA and HBsAg, irrespective of HBeAg status.

show abstract

Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection

Abstract: Linked content This article is linked to Mak et al and Mak and Yuen papers. To view these articles visit https://doi.org/10.1111/apt.14376 and https://doi.org/10.1111/apt.14684.

Cited by 5 publications

References 7 publications

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues

Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA

Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients

Contact Info

Product

Resources

About